• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Biomedical and Pharmaceutical Sciences
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 8 (2025)
Volume Volume 7 (2024)
Volume Volume 6 (2023)
Volume Volume 5 (2022)
Volume Volume 4 (2021)
Volume Volume 3 (2020)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 2 (2019)
Volume Volume 1 (2018)
Mohamed, M., Alaaeldin, E., Hussein, A., A. Sarhan, H. (2020). Liposomes and PEGylated liposomes as drug delivery system. Journal of Advanced Biomedical and Pharmaceutical Sciences, 3(2), 80-88. doi: 10.21608/jabps.2020.22937.1068
Marwa Mohamed; Eman Alaaeldin; Amal Hussein; Hatem A. Sarhan. "Liposomes and PEGylated liposomes as drug delivery system". Journal of Advanced Biomedical and Pharmaceutical Sciences, 3, 2, 2020, 80-88. doi: 10.21608/jabps.2020.22937.1068
Mohamed, M., Alaaeldin, E., Hussein, A., A. Sarhan, H. (2020). 'Liposomes and PEGylated liposomes as drug delivery system', Journal of Advanced Biomedical and Pharmaceutical Sciences, 3(2), pp. 80-88. doi: 10.21608/jabps.2020.22937.1068
Mohamed, M., Alaaeldin, E., Hussein, A., A. Sarhan, H. Liposomes and PEGylated liposomes as drug delivery system. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2020; 3(2): 80-88. doi: 10.21608/jabps.2020.22937.1068

Liposomes and PEGylated liposomes as drug delivery system

Article 5, Volume 3, Issue 2, April 2020, Page 80-88  XML PDF (785.89 K)
Document Type: Review Articles
DOI: 10.21608/jabps.2020.22937.1068
View on SCiNiTO View on SCiNiTO
Authors
Marwa Mohamed email ; Eman Alaaeldin; Amal Hussein; Hatem A. Sarhan
Department of Pharmaceutics, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt
Abstract
Generally, it has been thought that PEG-conjugated nanocarriers are non-immunogenic. However, many reports have revealed that unexpected immune responses occur with such PEG-conjugated nanocarriers. The Most important one is the rapid clearance of PEGylated nanocarriers upon repeated administration which is called accelerated blood clearance phenomenon involving the production of antibodies against nanocarrier components, which reduces the safety and effectiveness of the encapsulated therapeutic agent. Such immunogenicity of PEGylated nanocarriers is a potential concern in the evaluation and clinic use of PEGylated therapeutics. Accordingly, screening of the immunogenicity of nanocarriers-based therapeutics is a prerequisite before their adoption into clinical settings to disclose any possible interactions with immune system. This review gives an overview of PEGylated liposomes, immunogenicity of PEG, explanation of accelerated blood clearance (ABC) phenomenon, its mechanism, various factors affecting it and side effects of PEGylated liposomes.
Keywords
Accelerated blood clearance (ABC) phenomenon; anti-PEG IgM; PEGylated liposomes; polyethylene glycol (PEG); marginal zone (MZ)
Main Subjects
Pharmaceutics
Statistics
Article View: 2,448
PDF Download: 2,458
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.